TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference

JACKSONVILLE, Fla., May 1, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Disruptive Growth & Healthcare Conference, held May 8-9, 2018 at Reed Smith LLP in New York City.

Disruptive Growth & Healthcare Conference
Disruptive ImmunoTherapies Panel
Date: Wednesday, May 9th, 2018
Time: 9:30 AM ET
Location: Track 2 | Room C/D

TapImmune Company Presentation
Date: Wednesday, May 9th, 2018
Time: 11:35 AM ET
Location: Track 1 | Room A/B

About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be used without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.

For additional information, please visit: https://tapimmune.com/

To receive future press releases via email, please visit:

Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.

For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACT: Tiberend Strategic Advisors, Inc., Joshua Drumm, Ph.D. (Investors), (212) 375-2664, jdrumm@tiberend.com; David Schemelia (Media), (212) 375-2686, dschemelia@tiberend.com; TapImmune Inc., Aaron Santos, (904) 862-6490, asantos@tapimmune.com


View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-2018-disruptive-growth--healthcare-conference-300639637.html

SOURCE TapImmune Inc.

Back to news